IRIDEX (IRIX) Stock Price
IRIDEX Price
Over the last 19 years IRIDEX grew revenue by 2.0% annually, reaching 52.68 M USD. Earnings per share have declined at 26.3% per year over the last 6 years. For IRIDEX, the net margin of -8.4% is up versus -9.7% a few years ago. The consensus 12-month price target for IRIDEX is 2.04 USD, about 204.5% above where the stock trades today. Of 6 analysts, 0 rate the stock a buy — an overall Sell consensus. The stock trades about 5% above its 52-week low.
IRIDEX stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of IRIDEX over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how IRIDEX stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing IRIDEX's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | IRIDEX Price |
|---|---|
| 9/18/2026 | 0.67 USD |
| 9/17/2026 | 0.65 USD |
| 9/16/2026 | 0.67 USD |
| 9/15/2026 | 0.64 USD |
| 9/14/2026 | 0.64 USD |
| 9/13/2026 | 0.65 USD |
| 9/11/2026 | 0.66 USD |
| 9/10/2026 | 0.68 USD |
| 9/9/2026 | 0.68 USD |
| 9/8/2026 | 0.69 USD |
| 9/4/2026 | 0.70 USD |
| 9/3/2026 | 0.70 USD |
| 9/2/2026 | 0.72 USD |
| 9/1/2026 | 0.73 USD |
| 8/31/2026 | 0.72 USD |
| 8/28/2026 | 0.70 USD |
| 8/27/2026 | 0.71 USD |
| 8/26/2026 | 0.71 USD |
| 8/25/2026 | 0.72 USD |
| 8/24/2026 | 0.76 USD |
| 8/21/2026 | 0.76 USD |
| 8/20/2026 | 0.76 USD |
| 8/19/2026 | 0.80 USD |
| 8/18/2026 | 0.95 USD |
| 8/17/2026 | 0.88 USD |
| 8/14/2026 | 0.86 USD |
| 8/13/2026 | 0.82 USD |
| 8/12/2026 | 0.87 USD |
| 8/11/2026 | 0.89 USD |
| 8/10/2026 | 0.84 USD |
IRIDEX Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
IRIDEX Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 38.00 | 42.00 | 41.00 | 46.00 | 41.00 | 42.00 | 43.00 | 36.00 | 53.00 | 56.00 | 51.00 | 48.00 | 52.00 | 52.00 | 55.00 | 60.00 |
| 15.15 | 10.53 | -2.38 | 12.20 | -10.87 | 2.44 | 2.38 | -16.28 | 47.22 | 5.66 | -8.93 | -5.88 | 8.33 | – | 5.77 | 9.09 |
| 47.37 | 50.00 | 46.34 | 43.48 | 36.59 | 40.48 | 39.53 | 41.67 | 41.51 | 44.64 | 41.18 | 39.58 | 36.54 | 36.54 | 36.54 | 36.54 |
| 18.00 | 21.00 | 19.00 | 20.00 | 15.00 | 17.00 | 17.00 | 15.00 | 22.00 | 25.00 | 21.00 | 19.00 | 19.00 | 19.00 | 20.10 | 21.92 |
| 2.00 | 2.00 | – | -2.00 | -12.00 | -12.00 | -8.00 | -6.00 | -7.00 | -7.00 | -10.00 | -8.00 | -2.00 | -7.00 | -7.00 | -8.00 |
| 5.26 | 4.76 | – | -4.35 | -29.27 | -28.57 | -18.60 | -16.67 | -13.21 | -12.50 | -19.61 | -16.67 | -3.85 | -13.46 | -12.73 | -13.33 |
| 2.00 | 10.00 | – | -11.00 | -12.00 | -12.00 | -8.00 | -6.00 | -5.00 | -7.00 | -9.00 | -8.00 | -4.00 | -2.00 | – | 1.00 |
| 100.00 | 400.00 | – | – | 9.09 | – | -33.33 | -25.00 | -16.67 | 40.00 | 28.57 | -11.11 | -50.00 | -50.00 | – | – |
| 10.43 | 10.36 | 10.09 | 10.44 | 11.59 | 13.60 | 13.78 | 13.90 | 15.87 | 15.99 | 16.25 | 16.64 | 17.19 | 17.19 | 17.19 | 17.19 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales IRIDEX generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue IRIDEX retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare IRIDEX's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares IRIDEX has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against IRIDEX's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
IRIDEX stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
IRIDEX Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
IRIDEX business model & stock analysis
IRIDEX SWOT Analysis
Strengths
IRIDEX Corp is a leading global provider of innovative laser-based medical solutions. Their cutting-edge technology and expertise in ophthalmology have positioned them as a trusted brand in the industry.
The company's strong intellectual property portfolio gives them a competitive advantage and protects their innovations from being easily replicated by competitors.
IRIDEX Corp has established a strong distribution network worldwide, enabling them to reach a wide customer base and expand their market presence.
Weaknesses
The company heavily relies on a limited number of key customers for a significant portion of their revenue, making them vulnerable to changes in customer demand and potential loss of key accounts.
IRIDEX Corp faces intense competition from well-established players in the medical device industry. Their ability to differentiate themselves and maintain market share can be challenging.
As a technology-driven company, IRIDEX Corp is exposed to the risk of rapid technological advancements that could render their current products obsolete or less competitive.
Opportunities
The global demand for minimally invasive medical treatments is growing, presenting an opportunity for IRIDEX Corp to expand their market and offer their advanced laser-based solutions to a broader range of medical specialties.
Advancements in healthcare infrastructure and access to medical services in emerging markets provide IRIDEX Corp with an opportunity to tap into new geographical regions and increase their customer base.
The increasing prevalence of ocular diseases, such as glaucoma and diabetic retinopathy, presents a significant market opportunity for IRIDEX Corp to address unmet medical needs and develop targeted treatments.
Threats
IRIDEX Corp operates in a highly regulated industry, subject to rigorous compliance requirements. Any failure to comply with regulations and standards could result in legal and financial consequences.
The ongoing COVID-19 pandemic poses a threat to the company's operations, as it has disrupted global healthcare systems and caused delays in elective surgeries, leading to a potential decrease in demand for their products.
Intense competition and the potential entry of new players in the market pose a threat to IRIDEX Corp's market share and profitability.
IRIDEX Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
IRIDEX Segments
IRIDEX Revenue by Segment (1/2)
3 Years
5 Years
Max
Details
IRIDEX Revenue by Segment (2/2)
3 Years
5 Years
Max
Details
IRIDEX Revenue by Region
3 Years
5 Years
10 Years
Max
Details
IRIDEX Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
IRIDEX historical P/E ratio, EBIT multiple, and P/S ratio
IRIDEX annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down IRIDEX's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in IRIDEX's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare IRIDEX's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
IRIDEX shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current IRIDEX forecasts and price targets in September 2026
Analyst Price Targets 2026IRIDEX Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 5/15/2024 | Maintained | Hold | 57 | |
| 8/26/2022 | Downgrade | BuyHold | 57 | |
| 5/12/2021 | Maintained | Buy | 52 | |
| 3/3/2021 | Maintained | Buy | 52 | |
| 1/13/2021 | Maintained | Buy | 52 | |
| 5/12/2020 | Maintained | Buy | 57 | |
| 1/4/2019 | Maintained | Buy | 57 | |
| 1/4/2019 | Maintained | Buy | 57 | |
| 10/26/2018 | Maintained | Buy | 57 | |
| 12/21/2016 | Maintained | Buy | 52 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
IRIDEX Earnings Calls
IRIDEX Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 11/17/2026 | -0.04USD | - | 12.65 MUSD | - | 2026 Q3 |
| 8/18/2026 | -0.01USD | -0.07USD | 13.59 MUSD | - | 2026 Q2 |
| 5/19/2026 | -0.07USD | -0.03USD | 11.91 MUSD | - | 2026 Q1 |
| 3/26/2026 | -0.02USD | -0.01USD | 14.74 MUSD | - | 2025 Q4 |
| 11/11/2025 | -0.02USD | -0.09USD | 14.74 MUSD | - | 2025 Q3 |
| 8/12/2025 | -0.09USD | -0.06USD | 13.10 MUSD | - | 2025 Q2 |
| 3/27/2025 | -0.05USD | -0.05USD | 12.80 MUSD | - | 2025 Q1 |
| 11/12/2024 | -0.09USD | -0.12USD | 12.50 MUSD | - | 2024 Q3 |
| 8/8/2024 | -0.12USD | -0.16USD | 12.60 MUSD | - | 2024 Q2 |
| 5/14/2024 | -0.12USD | -0.21USD | 12.00 MUSD | - | 2024 Q1 |
IRIDEX shareholder structure
| % | Name |
|---|---|
5.81734% | |
3.36656% | |
2.33857% | |
2.16149% | |
2.04469% | |
1.50994% |
IRIDEX Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
29.92% | SEC ↗ | |
24.65% | SEC ↗ | |
24.10% | SEC ↗ | |
12.18% | SEC ↗ | |
11.00% | SEC ↗ | |
10.40% | SEC ↗ | |
10.40% | SEC ↗ | |
10.40% | SEC ↗ | |
10.40% | SEC ↗ | |
9.96% | SEC ↗ |
IRIDEX Executives and Management Board
7 members · avg. age 59 · 14 % women
Mr. Patrick Mercer (53)
President, Chief Executive Officer, Chief Operating Officer, Director · since 2018
1.11 M USD
Management
Mr. Bassem Bouhabib (49)
Vice President - International Sales
Mr. Romeo Dizon (67)
Chief Financial Officer · since 2025
Board of Directors
Mr. William Moore (76)
Independent Director · since 2007
Mr. Scott Shuda (59)
Independent Chairman of the Board
Ms. Beverly Huss (65)
Independent Director
Mr. Yu Hao Chen (44)
Independent Director
Frequently asked questions about IRIDEX
The business model of IRIDEX Corp focuses on developing, manufacturing, and marketing medical laser systems and delivery devices for the treatment of eye diseases and conditions. With a comprehensive portfolio of products, the company aims to provide innovative solutions to both ophthalmologists and patients. By leveraging its cutting-edge laser technology, IRIDEX Corp aims to improve the standards of care and enhance patient outcomes in the field of ophthalmology.
IRIDEX Corp is primarily active in the medical technology industry.
The main competitors of IRIDEX Corp in the market are Alcon Inc., Ellex Medical Lasers Ltd., and Lumenis Ltd.
IRIDEX Corp is a renowned medical technology company specializing in the development and commercialization of innovative laser systems for the treatment of various eye diseases. Founded in 1989, IRIDEX has since garnered a strong reputation for its cutting-edge products and advanced therapeutic solutions. The company boasts a rich history, marked by significant milestones and achievements in the field of ophthalmology. Guided by a commitment to revolutionize the way eye diseases are diagnosed and treated, IRIDEX remains at the forefront of the industry, continually striving to enhance patient outcomes through its state-of-the-art technologies.
IRIDEX Corp has achieved numerous significant milestones over the years. The company has successfully emerged as a leading provider of laser-based medical solutions, specializing in treating sight-threatening eye conditions. Notably, IRIDEX Corp introduced the innovative MicroPulse technology, which revolutionized the way retinal diseases are treated. Additionally, the company has expanded its product portfolio and global presence. IRIDEX Corp's dedication to technological advancements and commitment to enhancing patient outcomes have contributed to its position as a trusted name in ophthalmic healthcare.
IRIDEX Corp is primarily present in the United States.
IRIDEX Corp represents values of innovation, excellence, and patient-centricity. With a corporate philosophy centered around advancing patient care, IRIDEX Corp is committed to delivering cutting-edge medical solutions for eye diseases. The company strives to improve outcomes and enhance the quality of life for patients through the development and commercialization of minimally invasive laser-based medical devices. By combining state-of-the-art technology and a patient-first approach, IRIDEX Corp aims to revolutionize the treatment of retinal diseases and glaucoma. Through its commitment to innovation and dedication to improving patient outcomes, IRIDEX Corp has established itself as a leading player in the ophthalmic medical device industry.
Analysts currently set an average price target of 2.04 USD for the IRIDEX stock (median: 2.04 USD), implying +215.8 % versus the latest price. The consensus is based on 6 analyst ratings.
7 analysts currently rate the IRIDEX stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect IRIDEX to generate revenue of 52.52 M USD and earnings per share of -0.12 USD.
Converted at the current exchange rate, the IRIDEX share trades at 0.58 EUR (0.67 USD).
The IRIDEX share (IRIX) is listed on 1 stock exchanges, including: NASDAQ (IRIX).
IRIDEX Corporation is a leading company specializing in the development, manufacture, and sale of medical laser systems and accessories. The company offers a wide range of products and services targeting various customers including doctors, ophthalmologists, medical device providers, and surgical centers worldwide. The company specializes in two main divisions: ophthalmology and aesthetic dermatology. In the ophthalmology division, IRIDEX offers a variety of laser systems and system accessories focusing on the treatment of retinal diseases and glaucoma, as well as cosmetic and therapeutic procedures. The company is particularly known for its proven laser system, the "PASCAL Photocoagulator," which is considered one of the most advanced retinal laser therapy systems. IRIDEX's ophthalmology division also offers other innovative products such as the IRIS Medical SoftFit Gonioscope for glaucoma diagnosis. IRIDEX is also active in aesthetic dermatology, offering products for hair removal, wrinkle treatment, vascular treatment, and the treatment of common skin issues like acne. The flagship products in this area are the "GentleMAXPro" laser system and the multifunctional aesthetic system "Apogee+." The company generates revenue through the sale of devices and accessories, including consumables, as well as services such as training and support. IRIDEX sells its products in over 100 countries, targeting markets in Europe, North America, and Asia. It serves its customers directly through its subsidiaries or through distribution partners. The company's business model is based on a combination of research and development, marketing and sales, customer care, and efficiency assurance in production. IRIDEX engineers constantly work to improve the effectiveness and usability of their products, creating patient-oriented solutions based on scientifically proven results. IRIDEX has also entered into distribution agreements with global distributors to market and sell its products worldwide. IRIDEX aims to improve the standards and procedures of laser technology and continuously optimize patient care in the fields of ophthalmology and aesthetic dermatology. The company strives to build long-term relationships with clinicians and scientists to deliver advanced solutions in the medical device industry. In summary, IRIDEX is a company dedicated to advanced laser technology and accessories for ophthalmology and aesthetic dermatology. Through continuous innovation and collaborative partnerships, the company aims to support its customers with patient-oriented solutions. IRIDEX has already achieved significant milestones in its goal of establishing itself as the leading product line for global ophthalmology and aesthetic dermatology. IRIDEX Corporation is a leading company specialized in the development, manufacturing, and sale of medical laser systems and accessories. The company offers a wide range of products and services targeting various customers, including doctors, ophthalmologists, medical device providers, and surgical centers worldwide. The company is specialized in two main divisions: Ophthalmology and aesthetic dermatology. In the ophthalmology division, IRIDEX offers a variety of laser systems and system accessories focusing on the treatment of retinal diseases and glaucoma, as well as cosmetic and therapeutic procedures. The company is particularly known for its proven laser system, the "Pascal Photocoagulator," which is considered one of the most advanced retinal laser therapy systems. The IRIDEX ophthalmology division also offers other innovative products, such as the IRIS Medical SoftFit Gonioscope for glaucoma diagnosis. IRIDEX is also active in aesthetic dermatology, where it offers products for hair removal, wrinkle treatment, vascular treatment, and the treatment of common skin problems such as acne. The flagship products in this area are the "GentleMAXPro" laser system and the multifunctional aesthetic system "Apogee+." The company generates revenue through the sale of devices and accessory products, including consumables, and services such as training and support. IRIDEX sells its products in more than 100 countries, targeting markets in Europe, North America, and Asia. It serves its customers directly through its subsidiaries or through distribution partners. The company's business model is based on a combination of research and development, marketing and sales, customer support, and efficiency assurance in production. IRIDEX engineers constantly work to improve the effectiveness and usability of their products, creating patient-oriented solutions based on scientifically proven results. IRIDEX has also entered into distribution agreements with global distributors to market and sell its products worldwide. IRIDEX aims to improve the standards and procedures of laser technology and continuously optimize patient care in the fields of ophthalmology and aesthetic dermatology. The company strives to build long-term relationships with clinicians and scientists to deliver advanced solutions in the medical device industry. In summary, IRIDEX is a company dedicated to advanced laser technology and accessory products for ophthalmology and aesthetic dermatology. Through continuous innovation and collaborative partnerships, the company aims to support its customers with patient-oriented solutions. IRIDEX has already achieved significant milestones in its goal of establishing itself as a leading product line for global ophthalmology and aesthetic dermatology.
The expected revenue of IRIDEX is 52.52 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of IRIDEX is -2.06 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of IRIDEX is currently -5.58. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the IRIDEX stock.
The price-to-sales ratio (P/S) of IRIDEX is currently 0.22. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the IRIDEX stock.
The Eulerpool Quality Score for IRIDEX is 2/10.
The ISIN of IRIDEX is US4626841013. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of IRIDEX is 912341. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of IRIDEX is IRIX. The ticker symbol is used to trade IRIDEX shares on the stock exchange.
IRIDEX paid dividends every year for the past 0 years.
IRIDEX is assigned to the 'Health' sector.
The dividends of IRIDEX are distributed in USD.
IRIDEX stock
IRIDEX Peer Group
IRIDEX Ticker
IRIDEX FIGI
All fundamentals and in-depth analysis of IRIDEX
Our stock analysis for IRIDEX stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of IRIDEX. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.